

During a biological inflammatory response, patrolling leukocytes (white blood cells) release chemokines - a type of peptide cytokine - to summon other leukocytes. Inhibition of this process could provide a mechanism for new anti-inflammatory drugs.


Traditionally inhibition has been sought by blocking chemokine receptors with antagonists, but we have found useful molecules by inhibiting functional cell migration - with great success.

We would not have discovered **Broad-Spectrum Chemokine Inhibitors (BSCIs)** using a receptor antagonist approach as our functional screening approach has discovered a new biological target for anti-inflammatory drug design - the *sstr*₂ receptor.


➤ Sometimes **inflammation** is inappropriate and can **exacerbate** certain **diseases** for example cancer, arthritis and asthma.

➤ Due to their role in initiating inflammation chemokines are therefore a good target for anti-inflammatory drugs - for example BSCIs.

➤ NR58-3.14.3 is a BSCI. It is a cyclic peptide with the critical motif being **WIQ**.




➤ FX97L is a 40 pM BSCI.¹ The **Q** motif is mimicked by a caprolactam which retains the amide and has been found to be a successful pharmacological component.



FX97L 40 pM BSCI


➤ However, it has been discovered that BSCIs do not bind to chemokine receptors but to the **sstr**₂ receptor for **somatostatin**.

The aim of my project is to synthesise a catalogue of molecules analogous to both somatostatin and BSCIs to investigate the important part of the molecules for tipping *sstr*₂ from GH to BSCI




➤ Somatostatin is a peptide involved in **growth hormone (GH)** regulation.²

➤ It is a cyclic peptide with the critical motif being **KWF**.³



➤ An example of an *sstr*₂ ligand based on the **WKF** motif.




*sstr*₂ ligand based on WKF critical motif


➤ **Functional selectivity** is the ability for a receptor to have different functions depending on the molecule to which it is bound.

➤ The *sstr*₂ receptor therefore displays functional selectivity - when somatostatin is bound GH is affected but when BSCIs are bound chemokines are affected.⁴


Somatostatin analogue (KWF)




Hybrid? (KWFQ)



BSCI analogue (WFQ)



Synthesis:



➤ Future Work - The balance of BSCI vs. GH regulating activity for these compounds will be tested in a range of *in vitro* and *in vivo* models testing leukocyte migration, anti-inflammatory activity, *sstr*₂ binding and GH regulation.

Thanks to

Funxional Therapeutics Ltd, Dr D. J. Grainger & Dr D J Fox